Ningbo Tianyi Medical Equipment Co., Ltd. Announcement on the Reached 1% Share Repurchase Ratio and Progress of the Repurchase

Log in to the Sina Finance app and search for 【Information Disclosure】 to view more assessment tiers

Stock code: 301097 Stock abbreviation: Tianyi Medical Announcement No.: 2026-017

Ningbo Tianyi Medical Devices Co., Ltd.

Announcement on the Company’s Share Repurchase Ratio Reaching 1% and Repurchase Progress

The Company and all members of the Board of Directors warrant that the information disclosed in this announcement is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Ningbo Tianyi Medical Devices Co., Ltd. (hereinafter referred to as the “Company”) held the second meeting of the fourth session of the Board of Directors on January 12, 2026, and considered and approved the “Proposal on the Share Repurchase Plan of the Company.” It was agreed that the Company would use its own funds and bank loans to repurchase certain shares of the Company’s ordinary shares (A Shares) by means of centralized competitive trading, to implement an equity incentive plan or an employee stock ownership plan. The repurchase price for this repurchase shall not exceed RMB 65 per share (inclusive), the total repurchase funds shall not be less than RMB 60,000,000 (inclusive) and shall not exceed RMB 120,000,000 (inclusive). Based on the upper limit of the repurchase price and the lower and upper limits of the repurchase amount, the estimated number of shares to be repurchased is 0.923077 million shares to 1.846154 million shares, accounting for 1.57% to 3.13% of the Company’s current total share capital. The actual number of shares repurchased shall be subject to the number of shares actually repurchased upon the expiration of the repurchase period. The repurchase period shall be no more than 12 months from the date on which the Company’s Board of Directors deliberated and approved this share repurchase plan. If the relevant policies are adjusted by the state, this share repurchase plan shall be implemented according to the adjusted policies. For details, please refer to the Company’s disclosures on January 12, 2026 on the website of CNINFO (

In accordance with relevant provisions such as the “Rules for Share Repurchases by Listed Companies (2025 Revised)” and the “Self-Regulatory Guidance No. 9 for Listed Companies on the Shenzhen Stock Exchange—Share Repurchases (2025 Revised),” among others, where the Company’s repurchase shares as a proportion of its total share capital increase by each 1 percentage point, a disclosure shall be made within three trading days from the date on which that fact occurs; the Company hereby announces the progress of its share repurchases as follows:

I. Progress of the Company’s Share Repurchases

As of March 23, 2026, the Company has cumulatively repurchased 786,000 shares of the Company through centralized competitive trading using the special securities repurchase account, representing 1.3334% of the total A-share share capital. The highest成交 price was RMB 57.5 per share, the lowest成交 price was RMB 48.7 per share, and the total成交 amount was RMB 41,536,523 (excluding transaction fees). This share repurchase complies with the Company’s share repurchase plan and relevant laws and regulations.

II. Other Explanations

The timing of the Company’s share repurchases, the number of shares repurchased, the repurchase price, and the entrusted time period for centralized competitive trading all comply with the Company’s share repurchase plan and relevant provisions such as the “Rules for Share Repurchases by Listed Companies (2025 Revised)” and the “Self-Regulatory Guidance No. 9 for Listed Companies on the Shenzhen Stock Exchange—Share Repurchases (2025 Revised),” as follows:

(1) The Company did not repurchase shares during the following periods:

1. From the date on which a major event that may have a material impact on the trading prices of the Company’s securities and derivative instruments occurs, or during the decision-making process, until the date on which the information is disclosed in accordance with law;

2. Other circumstances as stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

(2) When the Company repurchases shares by means of centralized competitive trading, it meets the following requirements:

1. The entrusted price shall not be the price at which the Company’s stock is subject to the day’s trading price increase limit;

2. The Company shall not place repurchase orders during the Shenzhen Stock Exchange’s opening call auction, closing call auction, and during trading days when the stock price has no price increase/decrease limit;

3. Other requirements as stipulated by the China Securities Regulatory Commission and the Shenzhen Stock Exchange.

In the next phase, the Company will continue to implement this share repurchase plan within the repurchase period based on market conditions, and will timely fulfill its information disclosure obligations in accordance with relevant regulations. Investors are kindly requested to pay attention to investment risks.

This announcement is hereby issued.

Ningbo Tianyi Medical Devices Co., Ltd.

Board of Directors

March 24, 2026

For massive information and precise interpretation, it’s all on the Sina Finance app